Novavax, Inc. (NASDAQ:NVAX) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC decreased its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 11.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 376,968 shares of the biopharmaceutical company’s stock after selling 47,651 shares during the quarter. Nuveen Asset Management LLC owned about 0.24% of Novavax worth $3,031,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Spire Wealth Management bought a new position in shares of Novavax during the fourth quarter worth about $29,000. New Age Alpha Advisors LLC bought a new stake in Novavax in the fourth quarter valued at $35,000. KBC Group NV boosted its stake in Novavax by 97.0% during the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 3,917 shares during the period. TigerOak Management L.L.C. bought a new position in Novavax in the 4th quarter worth approximately $86,000. Finally, AlphaQuest LLC lifted its holdings in Novavax by 290.1% in the fourth quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 7,940 shares during the period. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Stock Performance

Shares of NVAX opened at $7.07 on Tuesday. Novavax, Inc. has a 52 week low of $5.01 and a 52 week high of $23.86. The stock has a fifty day moving average of $6.56 and a 200-day moving average of $7.78. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -3.13, a PEG ratio of 2.85 and a beta of 3.21.

Novavax (NASDAQ:NVAX) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $2.22. The company had revenue of $666.66 million for the quarter, compared to analyst estimates of $204.08 million. During the same quarter in the previous year, the firm earned ($1.05) EPS. The firm’s revenue was up 610.3% on a year-over-year basis. As a group, equities analysts forecast that Novavax, Inc. will post -1.46 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on NVAX shares. B. Riley reiterated a “buy” rating on shares of Novavax in a research report on Monday, May 19th. JPMorgan Chase & Co. dropped their price objective on shares of Novavax from $9.00 to $7.00 and set an “underweight” rating on the stock in a research note on Friday, May 9th. TD Cowen raised shares of Novavax to a “hold” rating in a research note on Thursday, February 27th. Finally, BTIG Research assumed coverage on shares of Novavax in a report on Friday, February 28th. They set a “buy” rating and a $19.00 price target for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Novavax has a consensus rating of “Hold” and an average price target of $19.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.